Form 4: REGENXBIO Director Kenneth Mills Receives Significant Equity Compensation Awards

REGENXBIO Inc. Director Kenneth T. Mills was granted 7,768 restricted stock units and 39,815 stock options as part of his equity compensation, aligning his interests with shareholders.

Summary

• Kenneth T. Mills, a Director of REGENXBIO Inc. (RGNX), reported the acquisition of equity securities on May 30, 2025.
• He was granted 7,768 shares of common stock underlying a time-based restricted stock unit (RSU) award, with a transaction price of $0.00.
• 100% of these RSU shares are scheduled to vest on May 1, 2026, contingent upon his continuous service to the Issuer.
• Additionally, Mr. Mills acquired 39,815 stock options with an exercise price of $8.85 per share.
• These stock options will vest in 12 equal monthly installments starting from May 30, 2025, also subject to his continuous service.
• The stock options have an expiration date of May 30, 2035.
• Following these transactions, Mr. Mills beneficially owns 482,871 shares of common stock directly and 39,815 derivative stock options directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates a director receiving equity compensation, which aligns their interests with shareholders and is a common incentive mechanism. It's a routine filing, not indicative of major positive or negative operational news.

Positives

• The granting of restricted stock units and stock options to a director aligns management's interests with those of shareholders, as the value of these awards is tied to the company's stock performance.
• Equity compensation is a common practice to attract and retain experienced board members and incentivize long-term value creation.

Risks

• The vesting of both the restricted stock units and stock options is subject to the continuous service of Kenneth T. Mills to REGENXBIO Inc., meaning the awards could be forfeited if his service ceases before vesting.
• The value of the stock options is dependent on the future market price of REGENXBIO's common stock exceeding the exercise price of $8.85; if the stock price remains below this, the options may hold no intrinsic value.

Future Outlook

The future outlook for these awards is tied to the director's continued service and the company's stock performance. The RSUs are set to vest in May 2026, and the options will vest monthly over the next year, providing potential future equity ownership and value realization.

Industry Context

The granting of equity compensation, such as restricted stock units and stock options, is a standard practice across various industries, particularly in biotechnology and growth-oriented sectors, to incentivize and retain key personnel, including directors, by aligning their financial interests with long-term company performance.

Stakeholder Impact

• Shareholders: The awards align the director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value. However, the exercise of options could lead to minor dilution if new shares are issued.
• Director (Kenneth T. Mills): Receives significant equity compensation, providing a direct financial incentive tied to the company's performance and continued service.

Next Steps

• Vesting of 7,768 restricted stock units on May 1, 2026, subject to continuous service.
• Monthly vesting of 39,815 stock options following May 30, 2025, subject to continuous service.
• Potential exercise of vested stock options by the director before the May 30, 2035 expiration date.

Key Dates

Keywords

REGENXBIO, RGNX, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership, Corporate Governance